Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study

Exclusion Criteria

• •1. Hypersensitivity to any component of the investigational drug
• •2. Inability to swallow oral medication
• •3. Participation in another interventional clinical trial within 4 weeks before enrollment, or planned participation during this study
• •4. Use of any investigational drug within 14 days prior to treatment initiation
• •5. Concurrent chemotherapy, radiotherapy, immunotherapy, or biologic therapy for breast cancer
• •6. Severe psychiatric disorders preventing compliance with informed consent, treatment, or follow-up procedures
• •7. Pregnancy, lactation, or plans for pregnancy in the near future
• •8. Other significant medical conditions or laboratory abnormalities that, in the investigator's judgment, make participation unsuitable